(Reuters) - Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S. approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback